A sustained release drug that can help people with age-related macular degeneration (AMD) has been given a global license agreement.
DelSiTech and Iveric Bio have announced the agreement so Iveric Bio can develop and commercialize new formulations of drug Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology.
As part of Iveric Bio’s lifecycle expansion plan for Zimura, the company says it is committed to developing sustained release technologies for the treatment of AMD. These technologies potentially could address patients being treated for geographic atrophy (GA) secondary to dry AMD and intermediate AMD.
Pravin Dugel, president of Iveric Bio: “We are thrilled to collaborate with the DelSiTech team on investigating additional sustained release formulations for Zimura with their drug delivery expertise and advanced technology and look forward to evaluating a sustained release formulation in GA and potentially earlier stages of AMD.
“Previously reported post-hoc analyses from GATHER1 suggest that Zimura may have the potential to impact AMD in preliminary stages before atrophy occurs in patients.
The post Finnish and US companies form exclusive agreement for development of sustained release drug appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.